MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

170.49 -3.34 (-1.92%)
Streaming Delayed Price Updated: 12:34 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
27 28 Next >
News headline image
3 Things Need to Align for The Next Big Market Move ↗
Currently, the small-cap index Russell 2000 is leading in momentum compared to the S&P 500 and the Nasdaq 100. Last Thursday is an important day for each of the indices as it represents the high of the... 
Via Talk Markets
News headline image
Musk Stirs Up A Hornet's Nest In Epstein Case, Apple WWDC Expectations, Kim Jong-Un Goes Ballistic And More: 5 Key Stories You May Have Missed From This Weekend ↗
Just as investors were hoping for an inflection higher, a strong non-farm payroll report proved to be the undoing of markets in the week ending June 3. Investors are still left to grapple with a fluid... 
Via Benzinga
News headline image
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
News headline image
Defensive Value: The Safety Trade of 2022 ↗
Defensive value sectors – Healthcare, Consumer Staples, Utilities – are doing ok so far in 2022. 
Via Talk Markets
News headline image
Is the Stock Market Looking for Temporary Relief? ↗
There is no doubt that the stock market is in a tough spot fundamentally with increasing interest rates, inflation, and a downward trend from the technical side. 
Via Talk Markets
News headline image
What Does a Trading Range Look Like? ↗
Buying ahead of taking out last week's high was premature. Getting overly negative unless we fail last week’s low is equally premature. 
Via Talk Markets
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
Can Big Tech Save the Day Again? ↗
Nasdaq spent most of the day green, only to close down .18% in the last few minutes of the session. 
Via Talk Markets
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
News headline image
Bill Gates' Tesla Short Bet Balloons, Astute Investors Reap Luna Windfall, Giga Shanghai Update And More: 5 Key Stories You May Have Missed Memorial Day Weekend ↗
The market is set to open following the long weekend in observance of the Memorial Day holiday. As investors look ahead to a fresh trading week, hoping for an extension of the... 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
News headline image
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats ↗
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
News headline image
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
3 Oversold Dividend Stocks to Buy Now ↗
These oversold dividend stocks provide an income opportunity. As the markets remain volatile, these stocks can weather to storm. 
Via InvestorPlace
News headline image
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
News headline image
3 Key Sectors To Watch With Hidden Momentum ↗
Mish’s Economic Modern Family looks to have found temporary support as each of the members has closed over the prior day's high providing relief from the downward trend. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts for May ↗
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
News headline image
Should Biotech Be On The Critical List? ↗
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
News headline image
Why We are Focusing on Commodities Over Equities ↗
Two commodities we are currently watching are sugar (CANE) and gold (GLD). Each is sitting on support from the 200-Day moving average. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story